Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.69 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.69 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.69 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6543213 | 0.98 | CHRNB2 (0.67) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL8236457 | 0.98 | HPGD (0.72) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL3156620 | 0.98 | HPGD (0.72) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL6482072 | 0.96 | HPGD (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL493736 | 0.96 | CHRNB2 (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27109069 | 0.91 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16373674 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1706129 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL29670708 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL29670691 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | BEBETTER MED INC. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4488275-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-118302423-A | Amine compound and use thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3768671-B1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-05-22 | — | — | EP | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023185821-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
| EP-1492786-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084949-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1337253-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002043734-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998018762-A1 | NEW DERIVATIVES OF DIVERSELY SUBSTITUTED CYCLICAL AMIDE SELECTIVE ANTAGONISTS OF THE HUMAN RECEPTOR NK3, PROCESS FOR OBTAINING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1998-05-07 | — | — | WO | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| EP-0034471-A1 | Piperidinoquinazolines and a process for the preparation thereof | ORION-YHTYMÄ OY (FI) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | CHRNB2 4298/4885CHRNA3 4068/4885CHRNA4 4329/4885 |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | CHRNB2 3613/4885CHRNA3 2681/4885CHRNA4 1460/4885 |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | CHRNB2 225/4885CHRNA3 262/4885CHRNA4 223/4885 |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | CYP46A1, CYP4A22, CYP2C19 | CHRNB2 4227/4885CHRNA3 4338/4885CHRNA4 3986/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | CHRNB2 4298/4885CHRNA3 4068/4885CHRNA4 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.